Literature DB >> 26423798

A vaccine formulated with the major outer membrane protein can protect C3H/HeN, a highly susceptible strain of mice, from a Chlamydia muridarum genital challenge.

Sukumar Pal1, Olga V Tatarenkova1, Luis M de la Maza1.   

Abstract

C3H/HeN female mice were vaccinated with native Chlamydia muridarum major outer membrane protein (MOMP), using Montanide+CpG or Alum+CpG as adjuvants. Negative control groups were immunized with ovalbumin (OVA) and the same adjuvants. As positive control, mice were inoculated intranasally with live Chlamydia. Mice were challenged in the ovarian bursa with 10(5) C. muridarum inclusion forming units. Six weeks after the genital challenge the animals were caged with male mice and monitored for pregnancy. Mice vaccinated with MOMP+Montanide+CpG developed high levels of C. muridarum-specific antibodies, with a high IgG2a/IgG1 ratio and neutralizing titres. Animals immunized using Alum+CpG had low antibody levels. Cellular immune responses were significantly higher in mice vaccinated with MOMP and Montanide+CpG, but not with Alum+CpG, when compared with negative controls. Following the genital challenge, only 20% (4/20) of mice vaccinated with MOMP+CpG+Montanide had positive vaginal cultures whereas 100% (9/9) of mice immunized with MOMP+CpG+Alum had positive cultures. Of the positive control animals inoculated with live Chlamydia only 15% (3/20) had positive vaginal cultures. In contrast, 100% (20/20) of mice immunized with OVA+CpG+Montanide, or minimal essential medium, had positive cultures. Following mating, 80% (16/20) of mice vaccinated with MOMP+CpG+Montanide, and 85% (17/20) of animals inoculated intranasally with live C. muridarum carried embryos in both uterine horns. No protection against infertility was observed in mice immunized with MOMP and CpG+Alum or OVA. In conclusion, this is the first time that a subunit vaccine has been shown to elicit a protective immune response in the highly susceptible C3H/HeN strain of mice against an upper genital challenge.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  Chlamydia muridarum; adjuvants; immunization; major outer membrane protein; mice

Mesh:

Substances:

Year:  2015        PMID: 26423798      PMCID: PMC4610632          DOI: 10.1111/imm.12520

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  92 in total

1.  CLASSIFICATION OF TRACHOMA VIRUS STRAINS BY PROTECTION OF MICE FROM TOXIC DEATH.

Authors:  S P WANG; J T GRAYSTON
Journal:  J Immunol       Date:  1963-06       Impact factor: 5.422

Review 2.  Chlamydia vaccine candidates and tools for chlamydial antigen discovery.

Authors:  Daniel D Rockey; Jie Wang; Lei Lei; Guangming Zhong
Journal:  Expert Rev Vaccines       Date:  2009-10       Impact factor: 5.217

3.  Mapping antigenic domains expressed by Chlamydia trachomatis major outer membrane protein genes.

Authors:  W Baehr; Y X Zhang; T Joseph; H Su; F E Nano; K D Everett; H D Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

4.  Immunoepidemiologic profile of Chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon- gamma.

Authors:  Craig R Cohen; Kasra M Koochesfahani; Amalia S Meier; Caixia Shen; Karuna Karunakaran; Beartrice Ondondo; Teresa Kinyari; Nelly R Mugo; Rosemary Nguti; Robert C Brunham
Journal:  J Infect Dis       Date:  2005-07-07       Impact factor: 5.226

5.  Immunotyping of Chlamydia trachomatis with monoclonal antibodies.

Authors:  S P Wang; C C Kuo; R C Barnes; R S Stephens; J T Grayston
Journal:  J Infect Dis       Date:  1985-10       Impact factor: 5.226

6.  Mapping of a surface-exposed B-cell epitope to the variable sequent 3 of the major outer-membrane protein of Chlamydia trachomatis.

Authors:  S Pal; X Cheng; E M Peterson; L M de la Maza
Journal:  J Gen Microbiol       Date:  1993-07

7.  Abrogation of attenuated lentivirus-induced protection in rhesus macaques by administration of depo-provera before intravaginal challenge with simian immunodeficiency virus mac239.

Authors:  Kristina Abel; Tracy Rourke; Ding Lu; Kristen Bost; Michael B McChesney; Christopher J Miller
Journal:  J Infect Dis       Date:  2004-09-24       Impact factor: 5.226

8.  Induction of infertility by the Chlamydia trachomatis mouse pneumonitis biovar in strains of mice that differ in their response to the 60 kDa heat shock protein.

Authors:  A Khamesipour; S Pal; E M Peterson; L M de la Maza
Journal:  J Reprod Fertil       Date:  1994-07

9.  Pelvic inflammatory disease and fertility. A cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results.

Authors:  L Weström; R Joesoef; G Reynolds; A Hagdu; S E Thompson
Journal:  Sex Transm Dis       Date:  1992 Jul-Aug       Impact factor: 2.830

Review 10.  Development status and future prospects for a vaccine against Chlamydia trachomatis infection.

Authors:  Louise M Hafner; David P Wilson; Peter Timms
Journal:  Vaccine       Date:  2013-08-22       Impact factor: 3.641

View more
  9 in total

1.  Immunization with Chlamydia psittaci plasmid-encoded protein CPSIT_p7 induces partial protective immunity against chlamydia lung infection in mice.

Authors:  Yuan Tan; Yumeng Li; Yang Zhang; Jian Yu; Yating Wen; Chuan Wang; Man Xu; Qian Chen; Chunxue Lu; Yimou Wu
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

Review 2.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

3.  Heterologous prime-boost vaccination based on Polymorphic protein D protects against intravaginal Chlamydia trachomatis infection in mice.

Authors:  Carolina Veaute; María Teresa Damiani; Romina Cecilia Russi; Diego Del Balzo; Agustín Luján; Ivana Gabriela Reidel; María Inés García
Journal:  Sci Rep       Date:  2022-04-22       Impact factor: 4.996

4.  Chlamydial Type III Secretion System Needle Protein Induces Protective Immunity against Chlamydia muridarum Intravaginal Infection.

Authors:  Ekaterina A Koroleva; Natalie V Kobets; Dmitrii N Shcherbinin; Naylia A Zigangirova; Maxim M Shmarov; Amir I Tukhvatulin; Denis Y Logunov; Boris S Naroditsky; Alexander L Gintsburg
Journal:  Biomed Res Int       Date:  2017-03-26       Impact factor: 3.411

5.  Soluble antigens derived from Coxiella burnetii elicit protective immunity in three animal models without inducing hypersensitivity.

Authors:  Anthony E Gregory; Erin J van Schaik; Alycia P Fratzke; Kasi E Russell-Lodrigue; Christina M Farris; James E Samuel
Journal:  Cell Rep Med       Date:  2021-12-06

6.  Chlamydia trachomatis vaccines for genital infections: where are we and how far is there to go?

Authors:  Luis M de la Maza; Toni L Darville; Sukumar Pal
Journal:  Expert Rev Vaccines       Date:  2021-04-28       Impact factor: 5.217

7.  Prophylactic Multi-Subunit Vaccine against Chlamydia trachomatis: In Vivo Evaluation in Mice.

Authors:  Christian Lanfermann; Sebastian Wintgens; Thomas Ebensen; Martin Kohn; Robert Laudeley; Kai Schulze; Claudia Rheinheimer; Johannes H Hegemann; Carlos Alberto Guzmán; Andreas Klos
Journal:  Vaccines (Basel)       Date:  2021-06-06

8.  The Chlamydia M278 Major Outer Membrane Peptide Encapsulated in the Poly(lactic acid)-Poly(ethylene glycol) Nanoparticulate Self-Adjuvanting Delivery System Protects Mice Against a Chlamydia muridarum Genital Tract Challenge by Stimulating Robust Systemic and Local Mucosal Immune Responses.

Authors:  Richa Verma; Rajnish Sahu; Saurabh Dixit; Skyla A Duncan; Guillermo H Giambartolomei; Shree R Singh; Vida A Dennis
Journal:  Front Immunol       Date:  2018-10-15       Impact factor: 7.561

9.  Spectroscopic analysis of chlamydial major outer membrane protein in support of structure elucidation.

Authors:  Robert W Hepler; Debbie D Nahas; Bob Lucas; Robin Kaufhold; Jessica A Flynn; Jennifer D Galli; Ryan Swoyer; James M Wagner; Amy S Espeseth; Joseph G Joyce; James C Cook; Eberhard Durr
Journal:  Protein Sci       Date:  2018-11       Impact factor: 6.725

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.